Stammdaten
Insmed Incorporated, ein biopharmazeutisches Unternehmen, entwickelt und vermarktet Therapien für Patienten mit ernsthaften und seltenen Erkrankungen. Das Unternehmen bietet ARIKAYCE für die Behandlung von Mycobacterium avium complex Lungenerkrankung als Teil eines Kombinationsantibiotika-Behandlungsschemas für erwachsene Patienten an. Es entwickelt auch Brensocatib, einen oralen reversiblen Inhibitor der Dipeptidylpeptidase 1 für die Behandlung von Patienten mit Bronchiektase und anderen Neutrophil-vermittelten Erkrankungen; und Treprostinil Palmitil Inhalationspulver, eine inhalierbare Formulierung eines Treprostinil-Prodrugs Treprostinil Palmitil für die Behandlung von pulmonaler arterieller Hypertonie und anderen seltenen Lungenerkrankungen. Insmed Incorporated wurde 1988 gegründet und hat seinen Hauptsitz in Bridgewater, New Jersey. KI
Unternehmen & Branche
| Name | INSMED Inc |
|---|---|
| Ticker | INSM |
| CIK | 0001104506 |
| Börse | Nasdaq |
| Sektor | Gesundheit |
| Industrie | Pharmazeutische Erzeugnisse |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 457669307 |
|---|---|
| ISIN | US4576693075 |
| Typ | Common Stock |
| Marktkapitalisierung | 22,31 Mrd. USD |
| Beta | 0,80 |
Sitz & Kontakt
| Sitz (Inkorporation) | VA |
|---|---|
| Geschäftsadresse | 700 US HIGHWAY 202/206, 08807 BRIDGEWATER, NJ |
| Telefon | 908-977-9900 |
| EIN (IRS) | 54-1972729 |
Listing & Historie
| Listing-Börsen | Nasdaq |
|---|---|
| Fiskaljahr-Ende | 31.12. |
| SEC-Filer-Status | Large accelerated filer |
Bewertung
| KBV (P/B) | 30,19 vs. 7,88 (2021) ▲ |
|---|---|
| KUV (P/S) | 36,79 vs. 17,16 (2021) ▲ |
| FCF-Rendite | -4,3 % vs. -11,5 % (2021) ▲ |
Qualität & Bilanz
| Bruttomarge | 79,7 % vs. 76,6 % (2021) ▲ |
|---|---|
| Operative Marge | -205,6 % vs. -199,0 % (2021) ▼ |
| Nettomarge | -210,5 % vs. -230,6 % (2021) ▲ |
| ROIC | -96,3 % vs. -42,5 % (2021) ▼ |
| Zinsdeckungsgrad | -14,9 vs. -9,3 (2021) ▼ |
| Forderungslaufzeit (DSO) | 85 T vs. 47 T (2021) ▲ |
| Lagerreichweite (DIO) | 392 T vs. 554 T (2021) ▼ |
| Verbindlichkeitslaufzeit (DPO) | 237 T vs. 296 T (2021) ▼ |
| Cash-Conversion-Cycle (CCC) | 240 T vs. 305 T (2021) ▼ |
Basis: SEC-XBRL-Jahresabschluss bis 31.12.2025, Multiples mit aktueller Marktkapitalisierung (trailing), Vergleich: GJ bis 2021. Kennzahlen erklärt →
Kennzahlen-Historie (5 Jahre) – Tabelle & Verlauf
| Kennzahl | 2021 | 2022 | 2023 | 2024 | 2025 | TTM* | Verlauf |
|---|---|---|---|---|---|---|---|
| Bewertung | |||||||
| KBV (P/B) | 7,88 | 30,82 | – | 43,40 | 50,46 | 31,65 | |
| KUV (P/S) | 17,16 | 11,05 | 15,03 | 34,05 | 61,49 | 27,22 | |
| FCF-Rendite | -11,5 % | -15,1 % | -12,0 % | -5,7 % | -2,6 % | -4,1 % | |
| Qualität & Bilanz | |||||||
| Bruttomarge | 76,6 % | 77,5 % | 78,5 % | 76,4 % | 79,7 % | 81,8 % | |
| Operative Marge | -199,0 % | -186,4 % | -232,5 % | -241,5 % | -205,6 % | -140,6 % | |
| Nettomarge | -230,6 % | -196,3 % | -245,6 % | -251,2 % | -210,5 % | -144,4 % | |
| ROIC | -42,5 % | -38,0 % | -86,0 % | -63,7 % | -96,3 % | -92,1 % | |
| Zinsdeckungsgrad | -9,3 | -17,3 | -8,7 | -10,3 | -14,9 | -14,0 | |
Basis: SEC-XBRL-Jahresabschlüsse, Multiples je Geschäftsjahr mit Marktkapitalisierung zum Bilanzstichtag (point-in-time).
TTM* = letzte zwölf Monate (vorläufig, ungeprüft): jüngstes Geschäftsjahr + laufendes YTD − Vorjahres-YTD aus den Quartalsberichten (10-Q); Bewertungs-Multiples gegen die aktuelle Marktkapitalisierung. Kein testierter Jahresabschluss.
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »
Glück Conviction Score™ ⓘ
ⓘ
INSM
INSMED Inc
Effektiv
Neutral
Handelsvolumen
Hoch
Insider
0,0
Keine Insider-Käufe
Institutionell
45,6
102 neu, 291 erhöht, -2851240K $ netto
Aktivist
34,6
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,71% (Stand: 30.06.2026)
Score-Verlauf (90 Tage)
Konviktions-Verlauf — oben stark · Mitte neutral · unten schwach
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (24 Monate)
Indexierte Darstellung (Start = 100) — die Kursform bleibt sichtbar, absolute Kurse sind angemeldeten Mitgliedern vorbehalten.
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bärisch | 10 % | 105.06 | -3.4 % vs SMA50 | |
| Kurs vs SMA200 | Bärisch | 15 % | 147.93 | -31.4 % vs SMA200 | |
| EMA20 vs EMA50 | Bärisch | 5 % | 106.49 | EMA50: 110.13 | |
| MACD-Histogramm | Bärisch | 10 % | -0.912 | Bearisch | |
| RSI(14) | Neutral | 10 % | 38.4 | Neutral (30–70) | |
| Stoch %K(14) | Bullisch | 5 % | 14.9 | Überverkauft | |
| ADX(14)+DI | Neutral | 10 % | 17.6 | +DI: 13.5 / −DI: 25.4 | |
| Z-Score(60) | Neutral | 5 % | -0.63 | In Range | |
| 52W-Position | Bärisch | 5 % | 8.0 % | Hoch 211.41 / Tief 91.88 | |
| Bollinger(20,2σ) | Bullisch | 5 % | 5.9 % | Upper 117.65 / Mid 109.06 / Lower 100.48 | |
| LinReg-Slope(60) | Neutral | 10 % | -0.0898 | R²=0.04 / annualisiert -21.2 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-07-23 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -4.828 | 105,62 | -509.933,36 | -55,8% | |
| 2026-07-23 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -5.872 | 106,43 | -624.956,96 | -68,3% | |
| 2026-07-09 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -2.335 | 117,62 | -274.642,70 | -30,0% | |
| 2026-07-09 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -5.005 | 116,55 | -583.332,75 | -63,8% | |
| 2026-07-09 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -3.359 | 118,52 | -398.108,68 | -43,5% | |
| 2026-07-06 | Flammer Martina M.D. | Officer, Chief Medical Officer | Open Market Sale | -4.854 | 109,02 | -529.183,08 | -57,9% | |
| 2026-07-06 | Flammer Martina M.D. | Officer, Chief Medical Officer | Open Market Sale | -7.448 | 110,60 | -823.748,80 | -90,1% | |
| 2026-06-25 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -12.091 | 102,34 | -1.237.392,94 | -135,3% | |
| 2026-06-25 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -3.723 | 104,28 | -388.234,44 | -42,5% | |
| 2026-06-25 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -2.456 | 105,27 | -258.543,12 | -28,3% | |
| 2026-06-25 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -1.836 | 103,10 | -189.291,60 | -20,7% | |
| 2026-06-25 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -1.292 | 106,27 | -137.300,84 | -15,0% | |
| 2026-06-22 | Smith Michael Alexander | Officer, Chief Legal Officer | Open Market Sale | -1.806 | 95,82 | -173.050,92 | -18,9% | |
| 2026-06-08 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -6.515 | 94,03 | -612.605,45 | -67,0% | |
| 2026-06-05 | Flammer Martina M.D. | Officer, Chief Medical Officer | Open Market Sale | -1.858 | 103,78 | -192.823,24 | -21,1% | |
| 2026-06-03 | Smith Michael Alexander | Officer, Chief Legal Officer | Open Market Sale | -2.159 | 102,27 | -220.800,93 | -24,1% | |
| 2026-06-03 | Adsett Roger | Officer, Chief Operating Officer | Open Market Sale | -2.370 | 102,27 | -242.379,90 | -26,5% | |
| 2026-06-03 | Bonstein Sara | Officer, Chief Financial Officer | Open Market Sale | -2.404 | 102,27 | -245.857,08 | -26,9% | |
| 2026-06-03 | Flammer Martina M.D. | Officer, Chief Medical Officer | Open Market Sale | -2.566 | 102,27 | -262.424,82 | -28,7% | |
| 2026-06-03 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -7.605 | 102,27 | -777.763,35 | -85,0% | |
| 2026-05-22 | Smith Michael Alexander | Officer, Chief Legal Officer | Open Market Sale | -6.149 | 108,47 | -666.982,03 | -72,9% | |
| 2026-05-18 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -5.753 | 105,32 | -605.905,96 | -66,3% | |
| 2026-05-18 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -11.836 | 106,39 | -1.259.232,04 | -137,7% | |
| 2026-05-18 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -7.975 | 106,97 | -853.085,75 | -93,3% | |
| 2026-05-14 | Flammer Martina M.D. | Officer, Chief Medical Officer | Open Market Sale | -10.479 | 117,54 | -1.231.701,66 | -134,7% | |
| 2026-05-13 | Flammer Martina M.D. | Officer, Chief Medical Officer | Open Market Sale | -4.470 | 112,76 | -504.037,20 | -55,1% | |
| 2026-05-13 | Adsett Roger | Officer, Chief Operating Officer | Open Market Sale | -5.837 | 116,18 | -678.142,66 | -74,1% | |
| 2026-05-13 | Flammer Martina M.D. | Officer, Chief Medical Officer | Open Market Sale | -3.384 | 116,18 | -393.153,12 | -43,0% | |
| 2026-05-13 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -13.283 | 116,18 | -1.543.218,94 | -168,7% | |
| 2026-05-13 | Smith Michael Alexander | Officer, Chief Legal Officer | Open Market Sale | -4.109 | 116,18 | -477.383,62 | -52,2% | |
| 2026-05-13 | Bonstein Sara | Officer, Chief Financial Officer | Open Market Sale | -8.272 | 116,18 | -961.040,96 | -105,1% | |
| 2026-05-11 | Flammer Martina M.D. | Officer, Chief Medical Officer | Open Market Sale | -12.119 | 100,35 | -1.216.141,65 | -133,0% | |
| 2026-05-11 | Flammer Martina M.D. | Officer, Chief Medical Officer | Open Market Sale | -830 | 101,18 | -83.979,40 | -9,2% | |
| 2026-05-04 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -433 | 134,18 | -58.099,94 | -6,4% | |
| 2026-05-04 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -5.318 | 137,01 | -728.619,18 | -79,7% | |
| 2026-05-04 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -2.721 | 137,86 | -375.117,06 | -41,0% | |
| 2026-05-04 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -1.247 | 139,09 | -173.445,23 | -19,0% | |
| 2026-05-04 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -599 | 135,18 | -80.972,82 | -8,9% | |
| 2026-05-04 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -381 | 139,60 | -53.187,60 | -5,8% | |
| 2026-04-16 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -2.246 | 142,99 | -321.155,54 | -35,1% | |
| 2026-04-16 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -5.373 | 143,81 | -772.691,13 | -84,5% | |
| 2026-04-16 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -2.255 | 144,66 | -326.208,30 | -35,7% | |
| 2026-04-16 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -825 | 145,79 | -120.276,75 | -13,2% | |
| 2026-04-06 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -787 | 161,73 | -127.281,51 | -13,9% | |
| 2026-04-06 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -8.478 | 163,23 | -1.383.863,94 | -151,3% | |
| 2026-04-06 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -1.434 | 164,01 | -235.190,34 | -25,7% | |
| 2026-04-01 | Adsett Roger | Officer, Chief Operating Officer | Open Market Sale | -6.715 | 163,18 | -1.095.753,70 | -119,8% | |
| 2026-04-01 | Adsett Roger | Officer, Chief Operating Officer | Open Market Sale | -62.344 | 164,95 | -10.283.642,80 | -1124,4% | |
| 2026-04-01 | Adsett Roger | Officer, Chief Operating Officer | Open Market Sale | -19.001 | 164,11 | -3.118.254,11 | -341,0% | |
| 2026-03-30 | Smith Michael Alexander | Officer, Chief Legal Officer | Open Market Sale | -19.638 | 150,98 | -2.964.945,24 | -324,2% | |
| 2026-03-19 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -1.629 | 142,17 | -231.594,93 | -25,3% | |
| 2026-03-19 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -4.537 | 143,42 | -650.696,54 | -71,1% | |
| 2026-03-19 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -4.533 | 144,11 | -653.250,63 | -71,4% | |
| 2026-03-05 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -2.128 | 147,54 | -313.965,12 | -34,3% | |
| 2026-03-05 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -3.899 | 146,66 | -571.827,34 | -62,5% | |
| 2026-03-05 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -2.589 | 145,27 | -376.104,03 | -41,1% | |
| 2026-03-05 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -2.083 | 144,23 | -300.431,09 | -32,8% | |
| 2026-02-24 | Smith Michael Alexander | Officer, Chief Legal Officer | Open Market Sale | -4.852 | 153,93 | -746.868,36 | -81,7% | |
| 2026-02-24 | Smith Michael Alexander | Officer, Chief Legal Officer | Open Market Sale | -15.771 | 156,53 | -2.468.634,63 | -269,9% | |
| 2026-02-24 | Smith Michael Alexander | Officer, Chief Legal Officer | Open Market Sale | -4.151 | 155,06 | -643.654,06 | -70,4% | |
| 2026-02-19 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -1.891 | 150,10 | -283.839,10 | -31,0% | |
| 2026-02-19 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -3.413 | 151,12 | -515.772,56 | -56,4% | |
| 2026-02-19 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -2.377 | 151,92 | -361.113,84 | -39,5% | |
| 2026-02-19 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -1.988 | 149,17 | -296.549,96 | -32,4% | |
| 2026-02-19 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -1.030 | 153,38 | -157.981,40 | -17,3% | |
| 2026-02-09 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -4.888 | 147,17 | -719.366,96 | -78,7% | |
| 2026-02-09 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -7.221 | 148,02 | -1.068.852,42 | -116,9% | |
| 2026-02-09 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -1.287 | 148,83 | -191.544,21 | -20,9% | |
| 2026-02-05 | Flammer Martina M.D. | Officer, Chief Medical Officer | Open Market Sale | -869 | 152,44 | -132.470,36 | -14,5% | |
| 2026-02-03 | Flammer Martina M.D. | Officer, Chief Medical Officer | Open Market Sale | -795 | 155,77 | -123.837,15 | -13,5% | |
| 2026-02-03 | Adsett Roger | Officer, Chief Operating Officer | Open Market Sale | -791 | 156,17 | -123.530,47 | -13,5% | |
| 2026-02-03 | Smith Michael Alexander | Officer, Chief Legal Officer | Open Market Sale | -640 | 156,27 | -100.012,80 | -10,9% | |
| 2026-02-03 | Bonstein Sara | Officer, Chief Financial Officer | Open Market Sale | -748 | 156,34 | -116.942,32 | -12,8% | |
| 2026-02-03 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -3.009 | 156,34 | -470.427,06 | -51,4% | |
| 2026-02-02 | Flammer Martina M.D. | Officer, Chief Medical Officer | Open Market Sale | -563 | 152,06 | -85.609,78 | -9,4% | |
| 2026-02-02 | Flammer Martina M.D. | Officer, Chief Medical Officer | Open Market Sale | -3.349 | 154,56 | -517.621,44 | -56,6% | |
| 2026-02-02 | Flammer Martina M.D. | Officer, Chief Medical Officer | Open Market Sale | -3.042 | 155,46 | -472.909,32 | -51,7% | |
| 2026-02-02 | Flammer Martina M.D. | Officer, Chief Medical Officer | Open Market Sale | -928 | 153,16 | -142.132,48 | -15,5% | |
| 2026-02-02 | Flammer Martina M.D. | Officer, Chief Medical Officer | Open Market Sale | -100 | 156,86 | -15.686,00 | -1,7% | |
| 2026-01-20 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -1.006 | 156,80 | -157.740,80 | -17,2% | |
| 2026-01-20 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -5.967 | 158,99 | -948.693,33 | -103,7% | |
| 2026-01-20 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -2.229 | 159,85 | -356.305,65 | -39,0% | |
| 2026-01-20 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -1.243 | 158,37 | -196.853,91 | -21,5% | |
| 2026-01-20 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -254 | 160,70 | -40.817,80 | -4,5% | |
| 2026-01-12 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -315 | 174,86 | -55.080,90 | -6,0% | |
| 2026-01-12 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -160 | 170,24 | -27.238,40 | -3,0% | |
| 2026-01-12 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -297 | 171,31 | -50.879,07 | -5,6% | |
| 2026-01-12 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -7.176 | 168,63 | -1.210.088,88 | -132,3% | |
| 2026-01-12 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -6.996 | 169,57 | -1.186.311,72 | -129,7% | |
| 2026-01-12 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -297 | 172,36 | -51.190,92 | -5,6% | |
| 2026-01-12 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -3.974 | 167,73 | -666.559,02 | -72,9% | |
| 2026-01-09 | Flammer Martina M.D. | Officer, Chief Medical Officer | Open Market Sale | -1.887 | 186,19 | -351.340,53 | -38,4% | |
| 2026-01-08 | Adsett Roger | Officer, Chief Operating Officer | Open Market Sale | -2.059 | 174,17 | -358.616,03 | -39,2% | |
| 2026-01-08 | Flammer Martina M.D. | Officer, Chief Medical Officer | Open Market Sale | -1.660 | 173,87 | -288.624,20 | -31,6% | |
| 2026-01-08 | Flammer Martina M.D. | Officer, Chief Medical Officer | Open Market Sale | -3.251 | 174,17 | -566.226,67 | -61,9% | |
| 2026-01-08 | Smith Michael Alexander | Officer, Chief Legal Officer | Open Market Sale | -1.053 | 174,17 | -183.401,01 | -20,1% | |
| 2026-01-08 | Bonstein Sara | Officer, Chief Financial Officer | Open Market Sale | -1.447 | 174,17 | -252.023,99 | -27,6% | |
| 2026-01-08 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -3.223 | 174,17 | -561.349,91 | -61,4% | |
| 2026-01-07 | Bonstein Sara | Officer, Chief Financial Officer | Open Market Sale | -1.678 | 175,07 | -293.767,46 | -32,1% | |
| 2026-01-07 | Flammer Martina M.D. | Officer, Chief Medical Officer | Open Market Sale | -1.434 | 175,84 | -252.154,56 | -27,6% | |
| 2026-01-07 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -2.357 | 175,07 | -412.639,99 | -45,1% | |
| 2026-01-07 | Adsett Roger | Officer, Chief Operating Officer | Open Market Sale | -802 | 175,07 | -140.406,14 | -15,4% | |
| 2026-01-07 | Smith Michael Alexander | Officer, Chief Legal Officer | Open Market Sale | -709 | 175,07 | -124.124,63 | -13,6% | |
| 2026-01-06 | Flammer Martina M.D. | Officer, Chief Medical Officer | Open Market Sale | -4.783 | 173,47 | -829.707,01 | -90,7% | |
| 2026-01-06 | Flammer Martina M.D. | Officer, Chief Medical Officer | Open Market Sale | -2.830 | 174,21 | -493.014,30 | -53,9% | |
| 2026-01-06 | Flammer Martina M.D. | Officer, Chief Medical Officer | Open Market Sale | -957 | 175,01 | -167.484,57 | -18,3% | |
| 2026-01-06 | Flammer Martina M.D. | Officer, Chief Medical Officer | Open Market Sale | -1.615 | 173,33 | -279.927,95 | -30,6% | |
| 2026-01-06 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -4.096 | 173,33 | -709.959,68 | -77,6% | |
| 2026-01-06 | Adsett Roger | Officer, Chief Operating Officer | Open Market Sale | -1.429 | 173,33 | -247.688,57 | -27,1% | |
| 2026-01-06 | Bonstein Sara | Officer, Chief Financial Officer | Open Market Sale | -1.517 | 173,33 | -262.941,61 | -28,8% | |
| 2026-01-06 | Smith Michael Alexander | Officer, Chief Legal Officer | Open Market Sale | -1.396 | 173,33 | -241.968,68 | -26,5% | |
| 2026-01-05 | Flammer Martina M.D. | Officer, Chief Medical Officer | Open Market Sale | -3.205 | 170,61 | -546.805,05 | -59,8% | |
| 2026-01-05 | Flammer Martina M.D. | Officer, Chief Medical Officer | Open Market Sale | -2.799 | 169,29 | -473.842,71 | -51,8% | |
| 2026-01-05 | Flammer Martina M.D. | Officer, Chief Medical Officer | Open Market Sale | -1.820 | 173,45 | -315.679,00 | -34,5% | |
| 2026-01-05 | Flammer Martina M.D. | Officer, Chief Medical Officer | Open Market Sale | -702 | 175,73 | -123.362,46 | -13,5% | |
| 2026-01-05 | Flammer Martina M.D. | Officer, Chief Medical Officer | Open Market Sale | -655 | 174,28 | -114.153,40 | -12,5% | |
| 2026-01-05 | Flammer Martina M.D. | Officer, Chief Medical Officer | Open Market Sale | -286 | 171,92 | -49.169,12 | -5,4% | |
| 2026-01-05 | Flammer Martina M.D. | Officer, Chief Medical Officer | Open Market Sale | -2.836 | 171,19 | -485.494,84 | -53,1% | |
| 2026-01-02 | Schaeffer Orlov S Nicole | Officer, Chief People Strategy Officer | Open Market Sale | -9.125 | 177,17 | -1.616.676,25 | -176,8% | |
| 2026-01-02 | Schaeffer Orlov S Nicole | Officer, Chief People Strategy Officer | Open Market Sale | -34.103 | 175,17 | -5.973.822,51 | -653,2% | |
| 2026-01-02 | Schaeffer Orlov S Nicole | Officer, Chief People Strategy Officer | Open Market Sale | -31.030 | 174,28 | -5.407.908,40 | -591,3% | |
| 2026-01-02 | Schaeffer Orlov S Nicole | Officer, Chief People Strategy Officer | Open Market Sale | -12.832 | 176,08 | -2.259.458,56 | -247,1% | |
| 2026-01-02 | Schaeffer Orlov S Nicole | Officer, Chief People Strategy Officer | Open Market Sale | -200 | 177,78 | -35.556,00 | -3,9% | |
| 2025-12-18 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -51 | 171,20 | -8.731,20 | -1,0% | |
| 2025-12-18 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -2.175 | 168,54 | -366.574,50 | -40,1% | |
| 2025-12-18 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -1.938 | 169,58 | -328.646,04 | -35,9% | |
| 2025-12-18 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -1.783 | 166,60 | -297.047,80 | -32,5% | |
| 2025-12-18 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -1.465 | 163,19 | -239.073,35 | -26,1% | |
| 2025-12-18 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -1.431 | 167,29 | -239.391,99 | -26,2% | |
| 2025-12-18 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -697 | 165,21 | -115.151,37 | -12,6% | |
| 2025-12-18 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -447 | 164,24 | -73.415,28 | -8,0% | |
| 2025-12-18 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -362 | 170,26 | -61.634,12 | -6,7% | |
| 2025-12-18 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -350 | 162,26 | -56.791,00 | -6,2% | |
| 2025-12-05 | SHAROKY MELVIN MD | Director | Open Market Sale | -20.000 | 205,01 | -4.100.200,00 | -448,3% | |
| 2025-12-04 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -2.222 | 205,66 | -456.976,52 | -50,0% | |
| 2025-12-04 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -4.516 | 204,62 | -924.063,92 | -101,0% | |
| 2025-12-04 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -2.921 | 206,49 | -603.157,29 | -65,9% | |
| 2025-12-04 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -1.040 | 207,42 | -215.716,80 | -23,6% | |
| 2025-12-01 | Flammer Martina M.D. | Officer, Chief Medical Officer | Open Market Sale | -1.450 | 205,98 | -298.671,00 | -32,7% | |
| 2025-12-01 | Flammer Martina M.D. | Officer, Chief Medical Officer | Open Market Sale | -5.886 | 207,03 | -1.218.578,58 | -133,2% | |
| 2025-12-01 | Flammer Martina M.D. | Officer, Chief Medical Officer | Open Market Sale | -1.559 | 207,73 | -323.851,07 | -35,4% | |
| 2025-11-24 | ANDERSON ELIZABETH M | Director | Open Market Sale | -5.000 | 204,58 | -1.022.900,00 | -111,8% | |
| 2025-11-17 | LEE LEO | Director | Open Market Sale | -17.594 | 194,49 | -3.421.857,06 | -374,1% | |
| 2025-11-17 | LEE LEO | Director | Open Market Sale | -24.076 | 196,61 | -4.733.582,36 | -517,6% | |
| 2025-11-17 | LEE LEO | Director | Open Market Sale | -15.174 | 197,40 | -2.995.347,60 | -327,5% | |
| 2025-11-17 | LEE LEO | Director | Open Market Sale | -14.944 | 195,39 | -2.919.908,16 | -319,3% | |
| 2025-11-17 | LEE LEO | Director | Open Market Sale | -3.212 | 193,51 | -621.554,12 | -68,0% | |
| 2025-11-14 | ANDERSON ELIZABETH M | Director | Open Market Sale | -10.000 | 195,87 | -1.958.700,00 | -214,2% | |
| 2025-11-11 | Flammer Martina M.D. | Officer, Chief Medical Officer | Open Market Sale | -10.622 | 190,33 | -2.021.685,26 | -221,1% | |
| 2025-11-11 | Flammer Martina M.D. | Officer, Chief Medical Officer | Open Market Sale | -5.467 | 188,38 | -1.029.873,46 | -112,6% | |
| 2025-11-11 | Flammer Martina M.D. | Officer, Chief Medical Officer | Open Market Sale | -2.913 | 191,04 | -556.499,52 | -60,8% | |
| 2025-11-11 | Flammer Martina M.D. | Officer, Chief Medical Officer | Open Market Sale | -12.224 | 189,36 | -2.314.736,64 | -253,1% | |
| 2025-11-03 | Smith Michael Alexander | Officer, Chief Legal Officer | Open Market Sale | -3.243 | 184,91 | -599.663,13 | -65,6% | |
| 2025-11-03 | Smith Michael Alexander | Officer, Chief Legal Officer | Open Market Sale | -1.572 | 187,15 | -294.199,80 | -32,2% | |
| 2025-11-03 | Smith Michael Alexander | Officer, Chief Legal Officer | Open Market Sale | -1.342 | 181,01 | -242.915,42 | -26,6% | |
| 2025-11-03 | Smith Michael Alexander | Officer, Chief Legal Officer | Open Market Sale | -1.400 | 187,97 | -263.158,00 | -28,8% | |
| 2025-11-03 | Smith Michael Alexander | Officer, Chief Legal Officer | Open Market Sale | -7.619 | 181,88 | -1.385.743,72 | -151,5% | |
| 2025-11-03 | Smith Michael Alexander | Officer, Chief Legal Officer | Open Market Sale | -4.286 | 182,60 | -782.623,60 | -85,6% | |
| 2025-11-03 | Smith Michael Alexander | Officer, Chief Legal Officer | Open Market Sale | -4.032 | 183,92 | -741.565,44 | -81,1% | |
| 2025-11-03 | Smith Michael Alexander | Officer, Chief Legal Officer | Open Market Sale | -3.636 | 185,93 | -676.041,48 | -73,9% | |
| 2025-09-12 | Schaeffer Orlov S Nicole | Officer, Chief People Strategy Officer | Open Market Sale | -7.304 | 146,57 | -1.070.547,28 | -117,1% | |
| 2025-09-12 | SHAROKY MELVIN MD | Director | Open Market Sale | -10.000 | 145,39 | -1.453.900,00 | -159,0% | |
| 2025-09-12 | Schaeffer Orlov S Nicole | Officer, Chief People Strategy Officer | Open Market Sale | -32.091 | 144,60 | -4.640.358,60 | -507,4% | |
| 2025-09-12 | Schaeffer Orlov S Nicole | Officer, Chief People Strategy Officer | Open Market Sale | -30.967 | 145,67 | -4.510.962,89 | -493,2% | |
| 2025-09-12 | Schaeffer Orlov S Nicole | Officer, Chief People Strategy Officer | Open Market Sale | -6.158 | 147,46 | -908.058,68 | -99,3% | |
| 2025-09-02 | Flammer Martina M.D. | Officer, Chief Medical Officer | Open Market Sale | -34.615 | 146,05 | -5.055.520,75 | -552,8% | |
| 2025-09-02 | Smith Michael Alexander | Officer, Chief Legal Officer | Open Market Sale | -8.300 | 144,16 | -1.196.528,00 | -130,8% | |
| 2025-09-02 | Smith Michael Alexander | Officer, Chief Legal Officer | Open Market Sale | -7.391 | 143,16 | -1.058.095,56 | -115,7% | |
| 2025-09-02 | Smith Michael Alexander | Officer, Chief Legal Officer | Open Market Sale | -4.944 | 145,18 | -717.769,92 | -78,5% | |
| 2025-09-02 | Smith Michael Alexander | Officer, Chief Legal Officer | Open Market Sale | -1.354 | 141,16 | -191.130,64 | -20,9% | |
| 2025-09-02 | Smith Michael Alexander | Officer, Chief Legal Officer | Open Market Sale | -1.183 | 145,89 | -172.587,87 | -18,9% | |
| 2025-09-02 | Smith Michael Alexander | Officer, Chief Legal Officer | Open Market Sale | -1.100 | 142,06 | -156.266,00 | -17,1% | |
| 2025-09-02 | Flammer Martina M.D. | Officer, Chief Medical Officer | Open Market Sale | -63.782 | 145,33 | -9.269.438,06 | -1013,5% | |
| 2025-09-02 | Flammer Martina M.D. | Officer, Chief Medical Officer | Open Market Sale | -35.245 | 143,16 | -5.045.674,20 | -551,7% | |
| 2025-09-02 | Flammer Martina M.D. | Officer, Chief Medical Officer | Open Market Sale | -28.063 | 144,05 | -4.042.475,15 | -442,0% | |
| 2025-09-02 | Flammer Martina M.D. | Officer, Chief Medical Officer | Open Market Sale | -19.066 | 141,27 | -2.693.453,82 | -294,5% | |
| 2025-09-02 | Flammer Martina M.D. | Officer, Chief Medical Officer | Open Market Sale | -5.877 | 142,03 | -834.710,31 | -91,3% | |
| 2025-08-20 | SHAROKY MELVIN MD | Director | Open Market Sale | -10.000 | 129,50 | -1.295.000,00 | -141,6% | |
| 2025-08-19 | Adsett Roger | Officer, Chief Operating Officer | Open Market Sale | -20.193 | 127,42 | -2.572.992,06 | -281,3% | |
| 2025-08-19 | Adsett Roger | Officer, Chief Operating Officer | Open Market Sale | -4.807 | 128,27 | -616.593,89 | -67,4% | |
| 2025-08-18 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -1.416 | 129,47 | -183.329,52 | -20,0% | |
| 2025-08-18 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -2.968 | 127,59 | -378.687,12 | -41,4% | |
| 2025-08-18 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -2.481 | 128,76 | -319.453,56 | -34,9% | |
| 2025-08-14 | Schaeffer Orlov S Nicole | Officer, Chief People Strategy Officer | Open Market Sale | -700 | 128,16 | -89.712,00 | -9,8% | |
| 2025-08-14 | Schaeffer Orlov S Nicole | Officer, Chief People Strategy Officer | Open Market Sale | -5.746 | 127,71 | -733.821,66 | -80,2% | |
| 2025-08-14 | Schaeffer Orlov S Nicole | Officer, Chief People Strategy Officer | Open Market Sale | -3.554 | 126,57 | -449.829,78 | -49,2% | |
| 2025-08-12 | SHAROKY MELVIN MD | Director | Open Market Sale | -10.000 | 121,58 | -1.215.800,00 | -132,9% | |
| 2025-08-04 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -3.199 | 109,68 | -350.866,32 | -38,4% | |
| 2025-08-04 | Flammer Martina M.D. | Officer, Chief Medical Officer | Open Market Sale | -8.715 | 109,50 | -954.292,50 | -104,3% | |
| 2025-08-04 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -1.693 | 108,80 | -184.198,40 | -20,1% | |
| 2025-08-04 | Lewis William | Director, Officer, Chair and CEO | Open Market Sale | -1.938 | 110,91 | -214.943,58 | -23,5% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
⚠ Vorläufige Daten: Erst 3597 von typischerweise 8414 Fonds (43 %) haben für das aktuelle 13F-Quartal eingereicht — Werte können sich in den kommenden Wochen noch deutlich ändern.
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| JPMORGAN CHASE & CO | 24.255.499 | 0 | 24.255.499 | 3.718.853.370 | Neu | +100,0% | |
| BlackRock, Inc. | 16.678.146 | 0 | 16.678.146 | 2.727.210.442 | Neu | +100,0% | |
| Darwin Global Management, Ltd. | 16.805.184 | 0 | 16.805.184 | 2.576.570.811 | Neu | +100,0% | |
| FMR LLC | 13.160.167 | 0 | 13.160.167 | 2.151.950.430 | Neu | +100,0% | |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 10.371.802 | 0 | 10.371.802 | 1.695.997.063 | Neu | +100,0% | |
| VANGUARD CAPITAL MANAGEMENT LLC | 9.642.131 | 0 | 9.642.131 | 1.576.681.262 | Neu | +100,0% | |
| BAKER BROS. ADVISORS LP | 7.421.111 | 0 | 7.421.111 | 1.213.500.071 | Neu | +100,0% | |
| Artisan Partners Limited Partnership | 6.527.301 | 0 | 6.527.301 | 1.067.344.315 | Neu | +100,0% | |
| Invesco Ltd. | 6.512.889 | 0 | 6.512.889 | 1.064.987.700 | Neu | +100,0% | |
| D. E. Shaw & Co., Inc. | 5.642.725 | 0 | 5.642.725 | 922.698.392 | Neu | +100,0% | |
| Capital International Investors | 5.595.194 | 0 | 5.595.194 | 914.890.382 | Neu | +100,0% | |
| STATE STREET CORP | 5.551.699 | 0 | 5.551.699 | 907.813.820 | Neu | +100,0% | |
| RTW INVESTMENTS, LP | 4.842.880 | 0 | 4.842.880 | 791.907.738 | Neu | +100,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 4.450.389 | 0 | 4.450.389 | 733.323.353 | Neu | +100,0% | |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3.092.807 | 0 | 3.092.807 | 505.737.000 | Neu | +100,0% | |
| AMERIPRISE FINANCIAL INC | 3.057.718 | 0 | 3.057.718 | 499.999.046 | Neu | +100,0% | |
| FRANKLIN RESOURCES INC | 2.617.251 | 0 | 2.617.251 | 427.972.899 | Neu | +100,0% | |
| CITADEL ADVISORS LLC | 2.613.071 | 0 | 2.613.071 | 427.289.370 | Neu | +100,0% | |
| NWI MANAGEMENT LP | 2.028.000 | 0 | 2.028.000 | 331.618.000 | Neu | +100,0% | |
| Orbis Allan Gray Ltd | 1.872.824 | 0 | 1.872.824 | 306.244.181 | Neu | +100,0% | |
| UBS Group AG | 1.737.481 | 0 | 1.737.481 | 284.112.894 | Neu | +100,0% | |
| BANK OF AMERICA CORP /DE/ | 1.502.281 | 0 | 1.502.281 | 245.652.979 | Neu | +100,0% | |
| Integral Health Asset Management, LLC | 1.500.000 | 0 | 1.500.000 | 245.280.000 | Neu | +100,0% | |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 1.468.459 | 0 | 1.468.459 | 240.122.429 | Neu | +100,0% | |
| SEI INVESTMENTS CO | 1.395.794 | 0 | 1.395.794 | 228.239.457 | Neu | +100,0% | |
| Capital World Investors | 1.362.291 | 0 | 1.362.291 | 222.743.856 | Neu | +100,0% | |
| VANGUARD FIDUCIARY TRUST CO | 1.354.516 | 0 | 1.354.516 | 221.490.456 | Neu | +100,0% | |
| MORGAN STANLEY | 1.331.542 | 0 | 1.331.542 | 217.734.151 | Neu | +100,0% | |
| MILLENNIUM MANAGEMENT LLC | 1.295.086 | 0 | 1.295.086 | 211.772.463 | Neu | +100,0% | |
| NORTHERN TRUST CORP | 1.294.000 | 0 | 1.294.000 | 211.594.881 | Neu | +100,0% | |
| Castle Hook Partners LP | 1.269.754 | 0 | 1.269.754 | 207.630.174 | Neu | +100,0% | |
| Paradigm Biocapital Advisors LP | 1.254.488 | 0 | 1.254.488 | 205.133.878 | Neu | +100,0% | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1.215.025 | 0 | 1.215.025 | 198.680.888 | Neu | +100,0% | |
| Duquesne Family Office LLC | 1.154.090 | 0 | 1.154.090 | 188.717.000 | Neu | +100,0% | |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 1.143.739 | 0 | 1.143.739 | 187.024.000 | Neu | +100,0% | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1.078.930 | 0 | 1.078.930 | 176.426.634 | Neu | +100,0% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.069.390 | 0 | 1.069.390 | 174.866.653 | Neu | +100,0% | |
| Fiera Capital Corp | 1.021.970 | 0 | 1.021.970 | 167.112.534 | Neu | +100,0% | |
| GOLDMAN SACHS GROUP INC | 942.646 | 0 | 942.646 | 154.141.406 | Neu | +100,0% | |
| AMERICAN CENTURY COMPANIES INC | 925.799 | 0 | 925.799 | 151.387.667 | Neu | +100,0% | |
| PRINCIPAL FINANCIAL GROUP INC | 916.464 | 0 | 916.464 | 149.860.193 | Neu | +100,0% | |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 902.666 | 0 | 902.666 | 147.603.944 | Neu | +100,0% | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 900.000 | 0 | 900.000 | 147.168.000 | Neu | +100,0% | |
| FIL Ltd | 828.947 | 0 | 828.947 | 135.549.413 | Neu | +100,0% | |
| Amundi | 804.977 | 0 | 804.977 | 131.629.839 | Neu | +100,0% | |
| Pictet Asset Management Holding SA | 1.220.353 | 1.102.248 | 118.105 | 129.804.038 | Aufgestockt | +10,7% | |
| Legal & General Group Plc | 787.079 | 0 | 787.079 | 128.703.161 | Neu | +100,0% | |
| RAYMOND JAMES FINANCIAL INC | 775.148 | 0 | 775.148 | 121.375.450 | Neu | +100,0% | |
| ALLIANCEBERNSTEIN L.P. | 688.734 | 0 | 688.734 | 119.867.265 | Neu | +100,0% | |
| Hood River Capital Management LLC | 688.554 | 0 | 688.554 | 112.592.350 | Neu | +100,0% |
Top-Fondshalter (Stand: 30.06.2026) ⓘ
⚠ Vorläufige Daten: Erst 3597 von typischerweise 8414 Fonds (43 %) haben für dieses Quartal eingereicht. Vollständigkeit erwartet bis 14.08.2026. Auswertungen (NEW/INC/DEC) sind noch zu konservativ — viele Spätfiler erscheinen aktuell als „Exits".
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) | Stimmkontrolle | Verlauf |
|---|---|---|---|---|---|---|---|
| Pictet Asset Management Holding SA | 1.220.353 | 1.102.248 | +10,7% | 129.804.038 | 23,90 | 90 % | 12 Q |
| Aberdeen Group plc | 577.437 | 277.016 | +108,4% | 61.566.333 | 11,34 | 100 % | 11 Q |
| Sumitomo Mitsui Trust Group, Inc. | 437.713 | 501.282 | -12,7% | 46.668.960 | 8,59 | 100 % | 3 Q |
| GATEWAY INVESTMENT ADVISERS LLC | 365.000 | 365.000 | 0,0% | 38.916.300 | 7,17 | 100 % | 3 Q |
| NEW YORK STATE COMMON RETIREMENT FUND | 304.236 | 293.546 | +3,6% | 32.437.642 | 5,97 | 100 % | 17 Q |
| Assenagon Asset Management S.A. | 218.270 | 63.259 | +245,0% | 23.271.947 | 4,29 | 100 % | 17 Q |
| Handelsbanken Fonder AB | 189.581 | 67.481 | +180,9% | 20.213.000 | 3,72 | 0 % | 17 Q |
| EULAV Asset Management | 150.000 | 92.000 | +63,0% | 15.993.000 | 2,94 | 100 % | 4 Q |
| Swedbank AB | 129.518 | 82.865 | +56,3% | 13.809.208 | 2,54 | 100 % | 9 Q |
| Y-Intercept (Hong Kong) Ltd | 101.908 | 0 | +100,0% | 10.865.431 | 2,00 | 100 % | 8 Q |
| J. Safra Sarasin Holding AG | 95.602 | 93.181 | +2,6% | 10.437.869 | 1,92 | 100 % | 4 Q |
| Asset Management One Co., Ltd. | 79.510 | 82.381 | -3,5% | 8.477.356 | 1,56 | 100 % | 3 Q |
| FJARDE AP-FONDEN /FOURTH SWEDISH NATIONAL PENSION FUND | 68.450 | 68.350 | +0,1% | 7.298.139 | 1,34 | 100 % | 3 Q |
| Atle Fund Management AB | 58.378 | 97.438 | -40,1% | 6.224.262 | 1,15 | 100 % | 3 Q |
| MCRAE CAPITAL MANAGEMENT INC | 56.836 | 35.145 | +61,7% | 6.059.854 | 1,12 | 0 % | 4 Q |
| Resona Asset Management Co.,Ltd. | 56.132 | 60.930 | -7,9% | 5.967.549 | 1,10 | 100 % | 3 Q |
| CULLEN/FROST BANKERS, INC. | 54.740 | 55.578 | -1,5% | 5.836.379 | 1,07 | 100 % | 13 Q |
| IFM Investors Pty Ltd | 53.953 | 42.740 | +26,2% | 5.752.469 | 1,06 | 100 % | 3 Q |
| SIMON QUICK ADVISORS, LLC | 50.047 | 50.065 | 0,0% | 5.336.011 | 0,98 | 0 % | 2 Q |
| OFI INVEST ASSET MANAGEMENT | 47.000 | 0 | +100,0% | 4.383.049 | 0,81 | 100 % | 1 Q |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 30.06.2026 | vorl. | 179 | 5,1 | 543 |
| 31.03.2026 | ✓ | 662 | 220,0 | 35.557 |
| 31.12.2025 | ✓ | 664 | 216,4 | 37.661 |
| 30.09.2025 | ✓ | 559 | 233,8 | 33.625 |
| 30.06.2025 | ✓ | 503 | 209,5 | 21.056 |
| 31.03.2025 | ✓ | 448 | 745,0 | 16.600 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) |
|---|---|---|
| VANGUARD PORTFOLIO MANAGEMENT LLC | 10.371.802 | 1.695.997.063 |
| VANGUARD CAPITAL MANAGEMENT LLC | 9.642.131 | 1.576.681.262 |
| Capital World Investors | 1.362.291 | 222.743.856 |
| VANGUARD FIDUCIARY TRUST CO | 1.354.516 | 221.490.456 |
| Paradigm Biocapital Advisors LP | 1.254.488 | 205.133.878 |
| VANGUARD ASSET MANAGEMENT, Ltd | 360.075 | 58.879.464 |
| Bridgewater Associates, LP | 295.579 | 48.333.078 |
| Davern Capital Partners, LP | 182.562 | 29.852.538 |
| SEB Asset Management AB | 165.576 | 27.074.962 |
| Qube Research & Technologies Ltd | 148.515 | 24.285.173 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| FMR LLC | 13.160.167 | 3.232.231 | +32.6 % | 2.151.950.430 |
| Artisan Partners Limited Partnership | 6.527.301 | 1.683.552 | +34.8 % | 1.067.344.315 |
| BlackRock, Inc. | 16.678.146 | 1.613.094 | +10.7 % | 2.727.210.442 |
| D. E. Shaw & Co., Inc. | 5.625.825 | 1.274.830 | +29.3 % | 919.934.904 |
| AMERIPRISE FINANCIAL INC | 3.057.718 | 1.088.861 | +55.3 % | 499.999.046 |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 1.468.459 | 1.035.938 | +239.5 % | 240.122.429 |
| CITADEL ADVISORS LLC | 2.182.571 | 1.025.276 | +88.6 % | 356.894.010 |
| JPMORGAN CHASE & CO | 24.150.499 | 950.987 | +4.1 % | 3.702.754.770 |
| BAKER BROS. ADVISORS LP | 7.421.111 | 828.365 | +12.6 % | 1.213.500.071 |
| AMERICAN CENTURY COMPANIES INC | 925.799 | 740.709 | +400.2 % | 151.387.667 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| Darwin Global Management, Ltd. | 16.805.184 | -4.128.093 | -19.7 % | 2.576.570.811 |
| Orbis Allan Gray Ltd | 1.872.824 | -2.307.133 | -55.2 % | 306.244.181 |
| Invesco Ltd. | 6.512.889 | -1.005.449 | -13.4 % | 1.064.987.700 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3.092.807 | -946.659 | -23.4 % | 505.737.000 |
| Jefferies Financial Group Inc. | 3.500 | -922.839 | -99.6 % | 572.320 |
| TWO SIGMA INVESTMENTS, LP | 237.017 | -725.139 | -75.4 % | 38.757.020 |
| Janus Henderson Group Ltd. | 419.304 | -381.251 | -47.6 % | 68.564.425 |
| Duquesne Family Office LLC | 1.154.090 | -327.662 | -22.1 % | 188.717.000 |
| LORD, ABBETT & CO. LLC | 397.261 | -323.637 | -44.9 % | 64.960.000 |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 902.666 | -318.430 | -26.1 % | 147.603.944 |
Zusätzlich aktuell von 314 Mutual Funds/ETFs gehalten (N-PORT). Alle Fondsgesellschaften & ihre 4-Quartals-Bewegungen →
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Δ-Balken |
|---|---|---|---|---|---|---|
| 22.07.2026 | JPMORGAN CHASE & CO. | Passiv (13G/A) | 4,70 % | 10.365.622 | -6,10 pp | |
| 15.05.2026 | Darwin Global Management, Ltd. (+1) | Passiv (13G/A) | 7,80 % | 16.805.184 | -1,90 pp | |
| 15.05.2026 | Darwin Global Master Fund, Ltd. | Passiv (13G/A) | 6,60 % | 14.182.375 | -2,90 pp | |
| 06.05.2026 | Abigail P. Johnson (+1) | Passiv (13G) | 6,10 % | 13.145.167 | Neu | |
| 30.04.2026 | Vanguard Capital Management | Passiv (13G) | 5,34 % | 11.514.893 | Neu | |
| 27.03.2026 | The Vanguard Group | Passiv (13G/A) | Ausstieg | 0 | -10,18 pp | |
| 21.01.2026 | BlackRock, Inc. | Passiv (13G/A) | 6,60 % | 14.121.445 | +1,50 pp | |
| 14.11.2025 | Darwin Global Management, Ltd. (+1) | Passiv (13G/A) | 9,70 % | 20.457.445 | +1,20 pp | |
| 14.11.2025 | Darwin Global Master Fund, Ltd. | Passiv (13G/A) | 9,50 % | 20.085.806 | +2,00 pp | |
| 14.11.2025 | T. Rowe Price Associates, Inc. | Passiv (13G/A) | 3,30 % | 6.932.009 | -2,60 pp | |
| 04.09.2025 | JPMORGAN CHASE & CO. | Passiv (13G/A) | 10,80 % | 23.014.584 | +2,90 pp | |
| 14.08.2025 | T. Rowe Price Associates, Inc. | Passiv (13G/A) | 5,90 % | 11.230.934 | Neu | |
| 30.07.2025 | JPMORGAN CHASE & CO. | Passiv (13G) | 7,90 % | 15.164.893 | Neu | |
| 17.07.2025 | BlackRock, Inc. | Passiv (13G/A) | 5,10 % | 9.729.641 | Neu | |
| 15.05.2025 | Darwin Global Management, Ltd. (+1) | Passiv (13G/A) | 8,50 % | 15.397.975 | +1,30 pp | |
| 15.05.2025 | Darwin Global Master Fund, Ltd. | Passiv (13G/A) | 7,50 % | 13.547.617 | +1,10 pp | |
| 14.02.2025 | Darwin Global Master Fund, Ltd. | Passiv (13G/A) | 6,40 % | 11.480.655 | +1,00 pp | |
| 14.02.2025 | Darwin Global Management, Ltd. (+1) | Passiv (13G/A) | 7,20 % | 12.960.538 | +1,50 pp | |
| 08.01.2025 | The Vanguard Group | Passiv (13G/A) | 10,18 % | 18.218.973 | +0,31 pp | |
| 14.11.2024 | T. ROWE PRICE ASSOCIATES, INC. | Passiv (13G/A) | 7,30 % | 12.580.981 | -0,20 pp | |
| 03.09.2024 | Darwin Global Master Fund, Ltd. | Passiv (13G) | 5,40 % | 9.314.373 | Neu | |
| 03.09.2024 | Darwin Global Management, Ltd. (+1) | Passiv (13G) | 5,70 % | 9.717.822 | Neu | |
| 16.02.2024 | T. Rowe Price Investment Management, Inc. | Passiv (13G/A) | 4,10 % | 5.850.606 | 0,00 pp | |
| 14.02.2024 | T. Rowe Price Investment Management, Inc. | Passiv (13G) | 4,10 % | 5.850.606 | -2,10 pp | |
| 14.02.2024 | T. ROWE PRICE ASSOCIATES, INC. | Passiv (13G/A) | 7,50 % | 10.779.225 | +0,10 pp | |
| 13.02.2024 | The Vanguard Group | Passiv (13G/A) | 9,87 % | 14.125.521 | -0,20 pp | |
| 25.01.2024 | . BlackRock, Inc. | Passiv (13G/A) | 8,00 % | 11.492.282 | -0,20 pp | |
| 22.01.2024 | : STATE STREET CORPORATION | Passiv (13G/A) | 4,15 % | 0 | -0,93 pp | |
| 13.11.2023 | The Vanguard Group | Passiv (13G/A) | 10,07 % | 14.410.356 | +0,44 pp | |
| 14.02.2023 | T. Rowe Price Investment Management, Inc. | Passiv (13G) | 6,20 % | 8.374.675 | Neu | |
| 14.02.2023 | Anthony Joonkyoo Yun, MD (+3) | Passiv (13G/A) | 4,33 % | 5.871.291 | -0,76 pp | |
| 14.02.2023 | T. ROWE PRICE ASSOCIATES, INC. | Passiv (13G/A) | 7,40 % | 9.977.911 | -0,30 pp | |
| 09.02.2023 | Janus Henderson Group plc | Passiv (13G/A) | 2,20 % | 2.996.252 | -4,50 pp | |
| 09.02.2023 | The Vanguard Group | Passiv (13G/A) | 9,63 % | 13.040.831 | +0,24 pp | |
| 03.02.2023 | . BlackRock, Inc. | Passiv (13G/A) | 8,20 % | 11.113.787 | +0,30 pp | |
| 03.02.2023 | : STATE STREET CORPORATION | Passiv (13G) | 5,08 % | 0 | Neu | |
| 10.08.2022 | T. ROWE PRICE ASSOCIATES, INC. | Passiv (13G/A) | 7,70 % | 9.247.165 | -5,20 pp | |
| 14.02.2022 | Anthony Joonkyoo Yun, MD (+3) | Passiv (13G/A) | 5,09 % | 6.025.706 | -0,90 pp | |
| 14.02.2022 | T. ROWE PRICE ASSOCIATES, INC. | Passiv (13G/A) | 12,90 % | 15.321.204 | +2,80 pp | |
| 10.02.2022 | Janus Henderson Group plc | Passiv (13G/A) | 6,70 % | 7.881.558 | +1,00 pp |
US Congress Trades (STOCK Act)
| Datum | Mitglied | Partei | Kammer | Typ | Betrag-Bereich |
|---|---|---|---|---|---|
| 03.10.2025 | Gilbert Cisneros | – | House | Verkauf | $1,001 – $15,000 |
| 16.06.2025 | Josh Gottheimer | – | House | Kauf | $1,001 – $15,000 |
Quelle: House eFD & Senate eFD (STOCK Act PTR). Betragsangaben sind Bereichsangaben — keine Exaktwerte. Tiefenanalyse für diese Aktie → · Alle Kongress-Bestände →
Finanzkennzahlen (SEC XBRL) ⓘ
Währung:
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-03-31 | 10-Q | – | -163.563.000 $ | -0,76 $ | 2.075.863.000 $ | 704.852.000 $ |
| 2025-12-31 | 10-K | – | -1.276.775.000 $ | -6,42 $ | 2.264.558.000 $ | 738.976.000 $ |
| 2025-09-30 | 10-Q | – | -370.021.000 $ | -1,75 $ | 2.360.736.000 $ | 945.571.000 $ |
| 2025-06-30 | 10-Q | – | -321.686.000 $ | -1,70 $ | 2.479.857.000 $ | 1.249.735.000 $ |
| 2025-03-31 | 10-Q | – | -256.583.000 $ | -1,42 $ | 1.802.735.000 $ | 99.159.000 $ |
| 2024-12-31 | 10-K | – | -913.772.000 $ | -5,57 $ | 2.025.231.000 $ | 285.379.000 $ |
| 2024-09-30 | 10-Q | – | -220.524.000 $ | -1,27 $ | 2.052.972.000 $ | 483.415.000 $ |
| 2024-06-30 | 10-Q | – | -300.609.000 $ | -1,94 $ | 1.810.118.000 $ | 38.818.000 $ |
| 2024-03-31 | 10-Q | – | -157.091.000 $ | -1,06 $ | 1.159.095.000 $ | -464.808.000 $ |
| 2023-12-31 | 10-K | – | -749.567.000 $ | -5,34 $ | 1.329.837.000 $ | -331.923.000 $ |
| 2023-09-30 | 10-Q | – | -158.933.000 $ | -1,11 $ | 1.324.873.000 $ | -289.357.000 $ |
| 2023-06-30 | 10-Q | – | -244.809.000 $ | -1,78 $ | 1.439.139.000 $ | -155.745.000 $ |
| 2023-03-31 | 10-Q | – | -159.764.000 $ | -1,17 $ | 1.517.717.000 $ | -44.653.000 $ |
| 2022-12-31 | 10-K | – | -481.534.000 $ | -3,91 $ | 1.656.435.000 $ | 87.951.000 $ |
| 2022-09-30 | 10-Q | – | -131.145.000 $ | -1,09 $ | 994.817.000 $ | -29.959.000 $ |
| 2022-06-30 | 10-Q | – | -95.645.000 $ | -0,80 $ | 1.053.354.000 $ | 44.241.000 $ |
| 2022-03-31 | 10-Q | – | -94.621.000 $ | -0,80 $ | 1.153.315.000 $ | 119.880.000 $ |
| 2021-12-31 | 10-K | – | -434.654.000 $ | -3,88 $ | 1.243.508.000 $ | 410.468.000 $ |
| 2021-09-30 | 10-Q | – | -112.714.000 $ | -0,96 $ | 1.311.771.000 $ | 504.842.000 $ |
| 2021-06-30 | 10-Q | – | -117.321.000 $ | -1,07 $ | 1.229.783.000 $ | 531.053.000 $ |
Umsatz nach Segmenten & Regionen ⓘ
Geschäftssegmente
| Segment | FY 2025 | FY 2024 | FY 2023 | FY 2022 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|
| ARIKAYCE | 433,8 Mio. | – | – | – | 71,5 % | Neu | |
| BRINSUPRI | 172,7 Mio. | – | – | – | 28,5 % | Neu | |
| Reportable Segment | – | 363,7 Mio. | 305,2 Mio. | 245,4 Mio. | – | – |
Quartalsverlauf
| Segment | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|
| ARIKAYCE | 114,3 Mio. | – | – | 80,3 % | – | |
| BRINSUPRI | 28,1 Mio. | – | – | 19,7 % | – | |
| Reportable Segment | – | 107,4 Mio. | 92,8 Mio. | – | – |
Regionen
| Region | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| US | 453,0 Mio. | 254,8 Mio. | 224,2 Mio. | 186,0 Mio. | 159,5 Mio. | 74,7 % | +77,8% | |
| Non Us | 153,5 Mio. | – | – | – | – | 25,3 % | Neu | |
| JP | – | 87,7 Mio. | 65,7 Mio. | 56,5 Mio. | 16,0 Mio. | – | – | |
| Europe And The Rest Of The World | – | 21,2 Mio. | 15,3 Mio. | 2,9 Mio. | 12,9 Mio. | – | – |
Quartalsverlauf
| Region | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q3 FY2024 | Q2 FY2024 | Q1 FY2024 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|---|
| US | 102,0 Mio. | 68,7 Mio. | 64,3 Mio. | 66,9 Mio. | 63,8 Mio. | 56,3 Mio. | 71,7 % | +52,6% | |
| Non Us | 40,3 Mio. | – | – | – | – | – | 28,3 % | Neu | |
| JP | – | 30,7 Mio. | 22,1 Mio. | 21,0 Mio. | 21,1 Mio. | 14,9 Mio. | – | – | |
| Europe And The Rest Of The World | – | 8,1 Mio. | 6,5 Mio. | 5,6 Mio. | 5,4 Mio. | 4,3 Mio. | – | – |
Quartalsergebnisse (Earnings) ⓘ
| Quartal | Stichtag | Verkündet | Umsatz | EPS |
|---|---|---|---|---|
| Q1 2026 | 31.03.2026 | 07.05.2026 | 306,0 Mio. USD | -0,76 |
| Q3 2025 | 30.09.2025 | 30.10.2025 | 142,3 Mio. USD | -1,75 |
| Q2 2025 | 30.06.2025 | 07.08.2025 | 107,4 Mio. USD | -1,70 |
| Q1 2025 | 31.03.2025 | 08.05.2025 | 92,8 Mio. USD | -1,42 |
| Q3 2024 | 30.09.2024 | 31.10.2024 | 93,4 Mio. USD | -1,27 |
| Q2 2024 | 30.06.2024 | 08.08.2024 | 90,3 Mio. USD | -1,94 |
| Q1 2024 | 31.03.2024 | 09.05.2024 | 75,5 Mio. USD | -1,06 |
| Q3 2023 | 30.09.2023 | 26.10.2023 | 79,1 Mio. USD | -1,11 |
| Q2 2023 | 30.06.2023 | 03.08.2023 | 77,2 Mio. USD | -1,78 |
Einreichungs-Historie (10-K / 10-Q / 20-F / 6-K)
SEC-Einreichungs-Historie der letzten sechs Jahre (Datum = US-Kalendertag,
SEC/ET): Quartalsberichte (10-Q) und Jahresberichte (10-K); ausländische
Emittenten (ADR/Foreign Private Issuer) reichen stattdessen Jahresberichte
(20-F/40-F) und Zwischenmitteilungen (6-K) ein — dort liegt im SEC-Index
keine Berichtsperiode vor, Periode und Verzögerung bleiben leer. Die Spalte „Verzögerung" zeigt die
Tage zwischen Berichtsstichtag und tatsächlicher Einreichung.
Suffix /A kennzeichnet nachträgliche Berichtigungen.
| Eingereicht (US) | Form | Berichtsperiode | Verzögerung | |
|---|---|---|---|---|
| 07.05.2026 | 10-Q | 31.03.2026 | 37 Tage | SEC » |
| 19.02.2026 | 10-K | 31.12.2025 | 50 Tage | SEC » |
| 30.10.2025 | 10-Q | 30.09.2025 | 30 Tage | SEC » |
| 07.08.2025 | 10-Q | 30.06.2025 | 38 Tage | SEC » |
| 08.05.2025 | 10-Q | 31.03.2025 | 38 Tage | SEC » |
| 20.02.2025 | 10-K | 31.12.2024 | 51 Tage | SEC » |
| 31.10.2024 | 10-Q | 30.09.2024 | 31 Tage | SEC » |
| 08.08.2024 | 10-Q | 30.06.2024 | 39 Tage | SEC » |
| 09.05.2024 | 10-Q | 31.03.2024 | 39 Tage | SEC » |
| 22.02.2024 | 10-K | 31.12.2023 | 53 Tage | SEC » |
| 26.10.2023 | 10-Q | 30.09.2023 | 26 Tage | SEC » |
| 03.08.2023 | 10-Q | 30.06.2023 | 34 Tage | SEC » |
| 04.05.2023 | 10-Q | 31.03.2023 | 34 Tage | SEC » |
| 23.02.2023 | 10-K | 31.12.2022 | 54 Tage | SEC » |
| 27.10.2022 | 10-Q | 30.09.2022 | 27 Tage | SEC » |
| 04.08.2022 | 10-Q | 30.06.2022 | 35 Tage | SEC » |
| 05.05.2022 | 10-Q | 31.03.2022 | 35 Tage | SEC » |
| 17.02.2022 | 10-K | 31.12.2021 | 48 Tage | SEC » |
| 28.10.2021 | 10-Q | 30.09.2021 | 28 Tage | SEC » |
| 05.08.2021 | 10-Q | 30.06.2021 | 36 Tage | SEC » |
| 06.05.2021 | 10-Q | 31.03.2021 | 36 Tage | SEC » |
| 25.02.2021 | 10-K | 31.12.2020 | 56 Tage | SEC » |
| 29.10.2020 | 10-Q | 30.09.2020 | 29 Tage | SEC » |
| 06.08.2020 | 10-Q | 30.06.2020 | 37 Tage | SEC » |
Kapitalerhöhungen & Emissions-Historie
Emissions-Historie aus den finalen SEC-Prospekten: Börsengang (424B4) und Kapitalerhöhungen (424B5, Folge-/Sekundärplatzierungen). Volumen = Brutto-Erlös (bei Börsengängen zusätzlich der Ausgabepreis). Wiederholte Kapitalerhöhungen deuten auf Verwässerung der Altaktionäre hin.
| Datum (US) | Art | Volumen | |
|---|---|---|---|
| 12.06.2025 | Kapitalerhöhung | $750,0 Mio · $96,00/Aktie | SEC » |
| 11.06.2025 | Kapitalerhöhung | $650,0 Mio | SEC » |
| 30.05.2024 | Kapitalerhöhung | $620,7 Mio · $51,50/Aktie | SEC » |
| 29.05.2024 | Kapitalerhöhung | $500,0 Mio | SEC » |
| 22.02.2024 | Kapitalerhöhung | $500,0 Mio | SEC » |
| 19.10.2022 | Kapitalerhöhung | $275,0 Mio · $20,00/Aktie | SEC » |
| 12.05.2021 | Kapitalerhöhung | $486,3 Mio | SEC » |
| 12.05.2021 | Kapitalerhöhung | $235,0 Mio · $25,00/Aktie | SEC » |
| 10.05.2021 | Kapitalerhöhung | $250,0 Mio | SEC » |
| 10.05.2021 | Kapitalerhöhung | $500,0 Mio | SEC » |
| 25.02.2021 | Kapitalerhöhung | $250,0 Mio | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). Beträge in US-Dollar.
Proxy-/Governance-Filings
Proxy-Statements (SEC DEF-14A-Familie) der letzten sechs Jahre: reguläre HV-Einladungen zur Aktionärsversammlung, Aktivisten-Proxy-Fights (contested / Non-Management-Solicitation) und M&A-Abstimmungen.
| Datum (US) | Kategorie | HV-Termin (US) | Stichtag (US) | Form | |
|---|---|---|---|---|---|
| 01.04.2026 | HV-Einladung | — | — | DEFA14A | SEC » |
| 01.04.2026 | HV-Einladung | 13.05.2026 Jahres-HV | 06.03.2026 | DEF 14A | SEC » |
| 04.04.2025 | HV-Einladung | — | — | DEFA14A | SEC » |
| 04.04.2025 | HV-Einladung | 15.05.2025 Jahres-HV | 07.03.2025 | DEF 14A | SEC » |
| 01.04.2024 | HV-Einladung | — | — | DEFA14A | SEC » |
| 01.04.2024 | HV-Einladung | 13.05.2024 Jahres-HV | 12.03.2024 | DEF 14A | SEC » |
| 31.03.2023 | HV-Einladung | — | — | DEFA14A | SEC » |
| 31.03.2023 | HV-Einladung | 11.05.2023 Jahres-HV | 14.03.2023 | DEF 14A | SEC » |
| 01.04.2022 | HV-Einladung | — | — | DEFA14A | SEC » |
| 01.04.2022 | HV-Einladung | 11.05.2022 Jahres-HV | 18.03.2022 | DEF 14A | SEC » |
| 01.04.2021 | HV-Einladung | — | — | DEFA14A | SEC » |
| 01.04.2021 | HV-Einladung | 12.05.2021 Jahres-HV | 19.03.2021 | DEF 14A | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). HV-Termin = Datum der Aktionärsversammlung, Stichtag (Record Date) = Nachweisstichtag für die Stimmberechtigung (aus dem Dokument extrahiert).
Kritische 8-K Meldungen ⓘ
| Datum | Meldung | Tags | Schwere | Filing | Auszug |
|---|---|---|---|---|---|
| 19.02.2026 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | n such a filing. ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain… |
| 16.05.2025 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | ITEM 5.02 – Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 17.04.2025 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | ITEM 5.02 – Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 20.02.2025 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | e in such a filing. ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of… |
| 13.05.2024 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | ITEM 5.02 – Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 11.05.2023 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | ITEM 5.02 – Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 23.05.2022 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | ITEM 5.02 - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 13.05.2022 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | ITEM 5.02 - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 17.02.2022 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 22.06.2021 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 18.05.2021 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | ITEM 5.02 - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 14.05.2020 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | ITEM 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 02.04.2020 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 30.01.2020 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | ITEM 5.02 – Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
8-K-Ereignisse (KI)
🔒 Die vollständige KI-Einordnung je 8-K ist Teil des Kunden-Abos — freischalten.
| Datum | Ereignis | Sentiment | Materialität | Zusammenfassung | Filing |
|---|---|---|---|---|---|
| 16.07.2026 | Sonstiges | 0,10 | 35 | Insmed Inc. hat eine Pressemitteilung über 12-Monats-Sicherheit und Wirksamkeit von Treprostinil Palmitil Atempulver in Patienten mit Pulmon… 🔒 | SEC |
| 15.05.2026 | HV-Abstimmung | 0,00 | 20 | Die jährliche Hauptversammlung der Insmed Incorporated fand am 13. Mai 2026 statt. Die Aktionäre stimmten über die Wahl von zwei Klassenmitg… 🔒 | SEC |
| 07.05.2026 | Quartalszahlen | 0,00 | 55 | INSMED gab am 7. Mai 2026 Finanzergebnisse für Q1 2026 (Quartal bis 31. März) via Pressemitteilung und Präsentation bekannt. Ohne Details zu… 🔒 | SEC |
| 07.04.2026 | Sonstiges | 0,60 | 65 | Insmed gab Topline-Ergebnisse aus der Phase-2b-CEDAR-Studie von Brensocatib bei Hidradenitis suppurativa bekannt. Die randomisierte, placebo… 🔒 | SEC |
| 23.03.2026 | Guidance-Update | 0,80 | 80 | INSMED kündigte positive Topline-Ergebnisse der Phase-3b-ENCORE-Studie für ARIKAYCE® gegen MAC-Lungenentzündung an, was den Weg zur Marktgen… 🔒 | SEC |
| 19.02.2026 | Personalwechsel | -0,20 | 35 | Director David W.J. McGirr wird sich nicht zur Wiederwahl als Class II Director stellen. Der planmäßige Rücktritt erfolgt nach Ablauf seines… 🔒 | SEC |
| 09.01.2026 | Sonstiges | 0,15 | 25 | INSMED präsentiert auf der JP Morgan Healthcare Conference am 12. Januar 2026; Webcast verfügbar über Investor Relations. | SEC |
Fail-to-Deliver (6 Monate) ⓘ
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-07-13 | 9.169 | 115,61 | 1.060.028 |
| 2026-07-01 | 297 | 106,62 | 31.666 |
| 2026-06-29 | 434 | 103,38 | 44.867 |
| 2026-06-26 | 2.267 | 104,47 | 236.833 |
| 2026-06-25 | 166 | 103,46 | 17.174 |
| 2026-06-22 | 96 | 95,80 | 9.197 |
| 2026-06-18 | 5 | 98,45 | 492 |
| 2026-06-15 | 105 | 97,85 | 10.274 |
| 2026-06-11 | 43 | 91,88 | 3.951 |
| 2026-06-08 | 9.904 | 94,22 | 933.155 |
| 2026-06-04 | 48 | 103,86 | 4.985 |
| 2026-05-21 | 22.069 | 107,91 | 2.381.466 |
| 2026-05-13 | 11.691 | 116,00 | 1.356.156 |
| 2026-05-08 | 224.501 | 105,00 | 23.572.605 |
| 2026-04-20 | 139.933 | 144,48 | 20.217.520 |
| 2026-04-16 | 3 | 146,74 | 440 |
| 2026-04-09 | 358 | 160,18 | 57.344 |
| 2026-04-06 | 6 | 162,43 | 975 |
| 2026-03-23 | 7 | 136,00 | 952 |
| 2026-03-10 | 206 | 143,13 | 29.485 |
| 2026-03-04 | 10 | 147,00 | 1.470 |
| 2026-03-03 | 67 | 146,32 | 9.803 |
| 2026-02-27 | 41 | 150,00 | 6.150 |
| 2026-02-26 | 2.007 | 148,61 | 298.260 |
| 2026-02-23 | 421 | 164,91 | 69.427 |
| 2026-02-19 | 922 | 151,11 | 139.323 |
| 2026-02-18 | 62 | 150,52 | 9.332 |
| 2026-02-12 | 11.161 | 148,43 | 1.656.627 |
| 2026-02-11 | 1.791 | 148,55 | 266.053 |
| 2026-02-06 | 1.432 | 151,03 | 216.275 |
| 2026-02-05 | 1.412 | 152,44 | 215.245 |